Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has demonstrated consistent cardioprotective effects in patients with type 2 diabetes mellitus (T2DM). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.